Leung Kam
National for Biotechnology Information, NLM, NIH, Bethesda, MD
Integrins are a family of heterodimeric glycoproteins on cell surfaces that mediate diverse biological events involving cell–cell and cell–matrix interactions (1). Integrins consist of an α and a β subunit and are important for cell adhesion and signal transduction. The αβ integrin is the most prominent receptor affecting tumor growth, tumor invasiveness, metastasis, tumor-induced angiogenesis, inflammation, osteoporosis, and rheumatoid arthritis (2-7). Expression of the αβ integrin is on tumor cells and activated endothelial cells, whereas expression is weak on resting endothelial cells and most normal tissues (6, 8, 9). The peptide sequence Arg-Gly-Asp (RGD) has been identified as a recognition motif used by extracellular matrix proteins (vitronectin, fibrinogen, laminin, and collagen) to bind to a variety of integrins, including αβ. Various radiolabeled antagonists have been introduced for imaging of tumors and tumor angiogenesis (10). Most cyclic RGD peptides are composed of five amino acids. Various cyclic RGD peptides exhibit selective inhibition of binding to αβ integrin (50% inhibition concentration (IC), 7–40 nM) but no inhibition of binding to αβ (IC, 600–4,000 nM) or αβ (IC, 700–5,000 nM) integrins (11). Various radiolabeled cyclic RGD peptides and peptidominetics have been found to have high accumulation in tumors in mice (12, 13). Of these developments, [F]galacto-c(RGDfK) has been evaluated in a number of clinical studies for imaging of αβ integrin in cancer patients (14-19). Both αβ and αβ integrins bind to vitronectin (20). However, while the αβ integrin is required for basic fibroblast growth factor–mediated angiogenesis, the αβ integrin is required for vascular endothelial growth factor–induced angiogenesis (21, 22). The peptide Lys-Cys-Arg-Gly-Asp-Cyc-Phe-Cys (NC100717) was identified with phage display screening to be a potent and selective binder to both αβ and αβ integrins (23). A new peptide, NC100692, was derived from NC100717 with addition of diamine dioxime to the ε-amine of Lys and the N-terminal end modified with a short polyethylene glycol unit. Hua et al. (24) reported the development of Tc-NC100692 for single-photon emission computed tomography (SPECT) imaging of αβ and αβ integrins in mice with hindlimb ischemia. Bach-Gansmo et al. (25) has performed a preliminary study in patients with breast cancer.
整合素是细胞表面的一类异源二聚体糖蛋白,介导涉及细胞间和细胞与基质相互作用的多种生物学事件(1)。整合素由一个α亚基和一个β亚基组成,对细胞黏附和信号转导很重要。αβ整合素是影响肿瘤生长、肿瘤侵袭性、转移、肿瘤诱导的血管生成、炎症、骨质疏松和类风湿性关节炎的最主要受体(2 - 7)。αβ整合素在肿瘤细胞和活化的内皮细胞上表达,而在静止的内皮细胞和大多数正常组织上表达较弱(6, 8, 9)。肽序列精氨酸 - 甘氨酸 - 天冬氨酸(RGD)已被确定为细胞外基质蛋白(玻连蛋白、纤维蛋白原、层粘连蛋白和胶原蛋白)用于结合多种整合素(包括αβ)的识别基序。已引入各种放射性标记的拮抗剂用于肿瘤和肿瘤血管生成的成像(10)。大多数环状RGD肽由五个氨基酸组成。各种环状RGD肽对αβ整合素的结合表现出选择性抑制(50%抑制浓度(IC),7 - 40 nM),但对αβ(IC,600 - 4,000 nM)或αβ(IC,700 - 5,000 nM)整合素的结合无抑制作用(11)。已发现各种放射性标记的环状RGD肽和拟肽在小鼠肿瘤中有高蓄积(12, 13)。在这些进展中,[F]半乳糖 - c(RGDfK)已在多项临床研究中用于癌症患者αβ整合素的成像(14 - 19)。αβ和αβ整合素都与玻连蛋白结合(20)。然而,虽然αβ整合素是碱性成纤维细胞生长因子介导的血管生成所必需的,但αβ整合素是血管内皮生长因子诱导的血管生成所必需的(21, 22)。通过噬菌体展示筛选鉴定出肽赖氨酸 - 半胱氨酸 - 精氨酸 - 甘氨酸 - 天冬氨酸 - 环 - 苯丙氨酸 - 半胱氨酸(NC100717)是αβ和αβ整合素的有效且选择性结合剂(23)。一种新的肽NC100692是从NC100717衍生而来,在赖氨酸的ε - 氨基上添加了二胺二肟,并在N末端用短聚乙二醇单元修饰进行了修饰。华等人(24)报道了用于后肢缺血小鼠中αβ和αβ整合素单光子发射计算机断层扫描(SPECT)成像的锝 - NC100692的研发。巴赫 - 甘斯莫等人(25)对乳腺癌患者进行了一项初步研究。